Mandate

Vinge advises Capillar in connection with Sweden’s first ever de-SPAC

Capillar and the minority shareholders have entered into an agreement to sell all shares in Spolargruppen Sverige AB, a Swedish leading player in pipe lining (so-called relining) and pipe flushing, to tbd30 AB (publ), a so called SPAC (Special Purpose Acquisition Company).

In connection with the proposed transaction, a process is initiated (so-called “de-SPAC” or company combination) which includes, among other things, that Nasdaq Stockholm AB examines the intended acquisition, application for listing and change of trading venue to Nasdaq First North Growth Market within the framework of Nasdaq Stockholm's regulations regarding SPACs.

As part of the continued financing, a number of institutional and other investors, including Lannebo Fonder and Carnegie Fonder, have undertaken to subscribe for 1,500,000 new class A shares in tbd30 in a directed new share issue at SEK 100 per share.

Vinges team primarily consists of Christina Kokko, Joacim Rydergård, Hannah Kajlinger and Philip Moré (M&A), Linnéa Sellström (Equity Capital Markets) as well as Matthias Schömer and Henrik Wastenson (Tax).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026